C-peptide is a protein secreted by the pancreatic beta cells in equimolar quantities with insulin, following the cleavage of proinsulin into insulin. Measurement of C-peptide is used as a surrogate marker of endogenous insulin secretory capacity. Assessing C-peptide levels can be useful in classifying the sub-type of diabetes as well as assessing potential treatment choices in the management of diabetes.
INTRODUCTION
Insulin secretory capacity can be assessed by measuring C-peptide, a protein secreted by the pancreas in equimolar quantities with insulin, following the enzymatic cleavage of proinsulin into insulin (see figure 1 ). C-peptide is an attractive surrogate marker of insulin secretion because it can be used in patients administered exogenous insulin therapy and it is more reflective of insulin secretion than insulin itself, due to the variable clearance of insulin by the liver before it reaches the peripheral circulation 1 . C-peptide metabolism largely occurs in the kidney through glomerular filtration and uptake by tubular cells from peritubular capillaries, with 5-10% normally excreted in the urine. This is in contrast to insulin, 50% of which is metabolised and extracted in the liver. The total quantity of C-peptide excreted in the urine per day represents 5 % of pancreatic secretion, compared to only 0.1 % of secreted insulin 2 . Consequently, despite equimolar secretion, C-peptide has a longer halflife of approximately 30 minutes compared with only 6 minutes for insulin and occurs in the blood in concentrations up to five times higher than insulin 3, 4 . 
C-peptide and differentiating subtypes of diabetes
The assessment of endogenous C-peptide production in diabetes can be useful in classifying the sub-type of diabetes. In a patient with young onset diabetes persistent Cpeptide production may reflect the honeymoon period of a patient with Type 1 diabetes, but also enduring C-peptide can be a feature of other types of diabetes including Type 2 diabetes where levels are typically high.
There is extensive evidence that C-peptide can be used to differentiate between the classification of Type 1 diabetes and Type 2 diabetes [6] [7] [8] [9] [10] . 
Measurement of C-peptide

Blood C-peptide
Standard measures of C-peptide involve blood samples collected either fasted or, most often, after a fixed stimulus (such as oral glucose, mixed meal or IV glucagon) 1, 17, 18 . Despite the established clinical utility of blood C-peptide measurement, its widespread use is limited.
In many instances this is due to practical restrictions associated with sample collection. Both insulin and C-peptide concentrations are widely considered to be unstable and require specific pre-analytical handling procedures with many laboratory providers stipulating the need for blood samples to be rapidly centrifuged after collection on ice and the serum or plasma immediately frozen following separation from cells 1, 19 . However, these strict handling protocols may not be necessary as there is evidence that C-peptide is stable for up to 24 hours on whole blood if collected into EDTA preservative 20 .
Urine C-peptide
There is a body of evidence that suggests 24 hour urine C-peptide (UCP) levels provide an accurate means of assessing beta cell-secretory capacity and correlate with both fasting and stimulated serum insulin and C-peptide 2, 8, 21, 22 .
However, the cumbersome nature and difficulties in obtaining an accurate and complete 24
hour urine collection has limited the utility of this test [23] [24] [25] . Urine samples collected over a period of four hours and single post stimulated UCP have been shown to be significantly correlated with serum insulin and serum C-peptide in non-diabetic subjects 26 , and in insulin treated diabetic patients 7 .
Correcting for creatinine adjusts urine C-peptide concentration for variation in urine concentration and enables the use of 'spot' urine samples in place of 24-h urine collection. Urinary C-peptide when collected in boric acid is stable for up to three days at room temperature making it possible to be collected remotely from the processing laboratory and even posted into the laboratory by patients 27 . Urine C-peptide creatinine ratio correlates strongly with blood C-peptide and has been validated in non-diabetics, type 1 diabetes, type 2 diabetes, adults and children 15, 16, [28] [29] [30] [31] [32] [33] [34] [35] .
C-peptide assays
Early assays for C-peptide were radioimmunoassays and suffered from poor analytical sensitivity and specificity and are time-consuming to perform (and therefore expensive) 1, 36, 37 . The introduction of non-isotopic assays (chemiluminescence, fluorescence, etc.) that utilise monoclonal antibodies has improved analytical sensitivity, specificity, reproducibility and reduced assay costs (to approximately £10). These technologies are also amenable to automation, allowing these assays to be incorporated into large high throughput clinical analysers. 
MATERIALS
Measuring range
The measuring range of the urine C-peptide assay is from 0.03 -133 nmol/L.
There is approximately 30% cross-reactivity with pro-insulin (see Note 3)
Roche assay used to measure creatinine in urine
Creatinine is analysed on the Roche P modular analyser (Roche Diagnostics, Mannheim, Germany). The test principle is a kinetic colorimetric assay based on the Jaffé reaction as described by Popper et al., 1937 and modified by Bartels et al. in 1972 39 .
In alkaline solution, creatinine forms a yellow-orange complex with picrate. The colour intensity is directly proportional to the concentration of creatinine in the urine sample and is measured photometrically at 500 nm.
The assay was calibrated on each day of analysis using a two point calibration with Roche Calibrator for Automated Systems calibration material, traceable to Isotope Dilution-Mass Spectrometry (ID-MS) reference method. Quality Control was performed on each day of analysis using Randox assayed urine control level 2 & 3
Measuring range, units
The measuring range for creatinine in urine is 0.36-57.5 mmol/L .Samples that have a creatinine concentration greater than this may be diluted 1:2 via the automatic re-run function, using saline as a diluent.
Interpretation of results
UCPCR is restricted to use in patients on insulin treatment to assess endogenous insulin secretion. Its role in patients not on insulin treatment is limited.
If the of UCPCR result is not in keeping with other clinical finding then we would recommend repeating the test especially if it is unexpectedly low. Patients tipping out boric acid preservative from urine collection tube, in a sample taking more than 3 days to reach the laboratory can result in artificially low results
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. We are not aware of any reason or experience a falsely high value. . The test is unlikely to be appropriate in patients with severe renal impairment.
What values are expected in the different subtypes?
The UCPCR result is best measured on a post prandial sample taken approximately two hours after a meal stimulus. The interpretation depends on the specific clinical scenario i. 
NOTES
1-Agreement of urine C-peptide measurements in different commercially
available assays -There is poor comparability between commercial and in-house Cpeptide assays making transferability of C-peptides values/cut-offs from research to clinical practice problematic [40] [41] [42] . International working groups (in the USA and Europe) are currently addressing the widely disparate values between analytical methods for both C-peptide and insulin 40, 42, 43 . The groups are combining efforts to improve standardisation with the aim of establishing a complete reference measurement system and certified primary reference materials based on pure biosynthetic insulin and C-peptide 43 .
2-Using other diluents in the Roche C-peptide assay-C-peptide is approximately 20
fold more concentrated in urine samples and therefore require dilution before analysis. We have found that the diluent must be proteinaceous (e.g. equine serum albumin) in order to achieve both a concentration and matrix that will generate a comparable and reproducible result. This has been shown for three different platforms measuring C-peptide (Roche, Immunlite and Centaur).(*unpublished data derived at the Blood Sciences Dept, RD&E)
3-Cross reactivity of the Roche assay with proinsulin-Proinsulin does cross react with the Roche assay (30% cross reactivity) despite the fact that the assay utilises two site monoclonal antibodies. However, proinsulin and split products exist in much lower concentrations than C-peptide in serum (< 2% in non-diabetics) and are therefore of little clinical significance except for in rare conditions such as insulinoma 44 . In addition, the total quantity of C-peptide excreted in the urine per day represents 5-10 % of pancreatic secretion, compared to only 0.05 % of secreted proinsulin (2-3 times lower than insulin of which only 0.1% is excreted into the urine 45 ). With only 30% cross reactivity in the Roche assay the contribution of proinsulin to urine Cpeptide measurement would be negligible. diabetes with 94 % sensitivity and 94% specificity (ROC AUC 0.94).
4-Making a diagnosis in insulin treated patients-
5-Monitoring the honeymoon period in Type 1 diabetes
In patients with Type 1 diabetes it is possible to measure the extent to which they are progressing through the honeymoon phase. UCPCR is highly correlated with the serum C peptide in a formal mixed tolerance test nmol/mmol will most likely require insulin therapy.
